Effect of the JAK2 inhibitor TG on DLBCL-cell survival. (A-B) Ly3, Ly10, DHL2, DHL6, and Ly19 DLBCL cells were treated with various doses of the JAK2 inhibitor TG for 48 hours. Survival was then assessed by flow cytometry. Bars represent means ± SD from 3 experiments. (C) Ly3 and DHL2 cells were exposed to various concentrations of TG for 24 hours and expression of c-myc and survivin was analyzed by Western blotting. (D) c-myc mRNA expression was analyzed by qRT-PCR (as described in “qRT-PCR”) in TG-treated DHL2 cells. Bars represent means ± SD from 3 experiments. (E) siRNA (250 and 500nm) targeting JAK2 and a nonsilencing control siRNA were transfected as described in “siRNA transfection” and DHL2 cells were harvested 24, 48, and 72 hours later. Cell lysates were immunoblotted with JAK2 and β-actin Abs. (F) c-myc expression in JAK2 siRNA- (250 and 500nM) and control siRNA (500nM)–transfected DHL2 cells was analyzed at 72 hours by qRT-PCR.